These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 26358172)

  • 1. Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis.
    Cohen A; Kamanda-Kosseh M; Recker RR; Lappe JM; Dempster DW; Zhou H; Cremers S; Bucovsky M; Stubby J; Shane E
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4208-14. PubMed ID: 26358172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.
    Cohen A; Stein EM; Recker RR; Lappe JM; Dempster DW; Zhou H; Cremers S; McMahon DJ; Nickolas TL; Müller R; Zwahlen A; Young P; Stubby J; Shane E
    J Clin Endocrinol Metab; 2013 May; 98(5):1971-81. PubMed ID: 23543660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
    Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
    Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
    J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
    J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ; Tsai JN; Jiang LA; Lee H
    Bone; 2017 May; 98():54-58. PubMed ID: 28286299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.
    Minne H; Audran M; Simões ME; Obermayer-Pietsch B; Sigurðsson G; Marín F; Dalsky GP; Nickelsen T;
    Curr Med Res Opin; 2008 Nov; 24(11):3117-28. PubMed ID: 18838053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.
    Shane E; Shiau S; Recker RR; Lappe JM; Agarwal S; Kamanda-Kosseh M; Bucovsky M; Stubby J; Cohen A
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1528-e1540. PubMed ID: 34849989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
    Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
    J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis.
    Leder BZ; Neer RM; Wyland JJ; Lee HW; Burnett-Bowie SM; Finkelstein JS
    J Clin Endocrinol Metab; 2009 Aug; 94(8):2915-21. PubMed ID: 19435827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
    Senn C; Günther B; Popp AW; Perrelet R; Hans D; Lippuner K
    Osteoporos Int; 2014 Jul; 25(7):1945-51. PubMed ID: 24760244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
    J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
    Eastell R; Nickelsen T; Marin F; Barker C; Hadji P; Farrerons J; Audran M; Boonen S; Brixen K; Gomes JM; Obermayer-Pietsch B; Avramidis A; Sigurdsson G; Glüer CC
    J Bone Miner Res; 2009 Apr; 24(4):726-36. PubMed ID: 19049337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial.
    Cohen A; Shiau S; Nair N; Recker RR; Lappe JM; Dempster DW; Nickolas TL; Zhou H; Agarwal S; Kamanda-Kosseh M; Bucovsky M; Williams JM; McMahon DJ; Stubby J; Shane E
    J Clin Endocrinol Metab; 2020 Oct; 105(10):e3540-56. PubMed ID: 32876328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
    J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
    Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.